Why the study?
Does continuous infusion therapy reduce toxicity and preserve efficacy compared to classical intravenous bolus injection in patients receiving doxorubicin or daunorubicin?
Population
Patients receiving doxorubicin or daunorubicin
Comparison
Continuous infusion therapy vs Classical intravenous bolus injection
Design
Review
Authors
Loading...
May reduce doxorubicin toxicity via continuous infusion; leaves open efficacy preservation without phase III data.
Does continuous infusion therapy reduce toxicity and preserve efficacy compared to classical intravenous bolus injection in patients receiving doxorubicin or daunorubicin?
While continuous infusion of doxorubicin may reduce toxicity compared to bolus injection, comparative phase III trials are needed to confirm preservation of efficacy.
Jacques Robert (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: